AGP Executive Report

Prostate Cancer Diagnostics: ProsTIC26 highlighted PRIMARY2, using PSMA PET to better manage men with equivocal mpMRI (PI-RADS 2–3) and persistent risk, aiming to reduce unnecessary biopsies. Risk Stratification in Prostate Cancer: Another ProsTIC26 talk mapped how PSMA PET could refine D’Amico-style risk groups and “very-high-risk” categories for more tailored care. Next-Gen Prostate Theranostics: ProsTIC26 also focused on Lu-PSMA combination strategies to overcome resistance, weighing options like AR pathway inhibitors, chemo, T-cell engagers, antibody-drug conjugates, and DDR inhibitors. Menopause & Misinformation: Xand van Tulleken’s investigation targets the menopause supplement boom, arguing social media and fear around HRT have fueled risky “HRT alternatives.” Nigeria Pharma Policy: NAFDAC says its “5+5” and Ceiling List rules are boosting local drug manufacturing and cutting import dependence. Heart Failure Research: A gut-bacteria compound from pomegranates/walnuts (urolithin A) improved HFpEF heart function in models, but human trials are still needed. Cancer Care Tech: ORFAN-MAESTRIA reports AI can predict cardioembolic stroke and atrial fibrillation from routine cardiac CT scans. Drug Safety: India warns about suspected counterfeit Abhayrab rabies vaccine batches, urging dose verification. Mental Health & Sports: Reviews link pickleball to better wellbeing and padel to confidence/anxiety effects, while studies also explore loneliness, nightmares, and AI companions’ mixed impacts.

Drug Safety & Fraud: Australia’s regulator alleges Medtronic misled patients and doctors about real-world performance of its Intellis spinal cord stimulator, raising informed-consent concerns. Public Health & Access: India’s drug regulator flagged a suspected counterfeit batch of the anti-rabies vaccine Abhayrab, urging dose verification after “misbranded” vials were seized. Mental Health & Suicide Prevention: New research links rising loneliness in US veterans to higher psychiatric burden and suicide risk, while another report highlights how an “overwhelmed mind” can show up as forgetfulness and freezing. AI & Relationships: Study finds AI companions can improve mental health but may weaken offline connections, especially with augmented-reality interactions. Neuroscience & Sleep: Scientists report previously unknown brainwave chains that help organize memory during REM sleep. Aging & Dementia: Voice disorders may signal dementia risk—research suggests a 58% higher risk without hearing loss. Respiratory Risk: Childhood air pollution exposure may interact with COPD genetic risk, affecting lung function growth. Nutrition & Longevity: A large UK study finds longevity diets may differ for men and women, with whole-grain Mediterranean patterns benefiting women most. Pharma Business: Novartis India plans therapy-aligned acquisitions and deeper reach into Tier 2/3 markets; RPG Life Sciences plans Rs 500 crore to boost manufacturing and API capabilities. Oncology Pipeline: ProsTIC updates include neoadjuvant 177Lu-PSMA approaches and PETomics using PET imaging plus ctDNA to predict response. Care Quality: A carer was arrested after an alleged overdose harmed an 83-year-old dementia patient, underscoring long-term care safety risks.

Medical Devices & Trade: Qatar’s QMED 2026 (Oct. 14–16) adds Apex Health as a strategic sponsor, spotlighting regional healthcare capacity-building and medical tech partnerships. Oncology Research: At ProsTIC 2026, investigators shared early moves to bring PSMA radioligand therapy forward in prostate cancer, including a phase 1 neoadjuvant 177Lu-PSMA-I&T plus moderately hypofractionated radiotherapy plan for high-risk localized disease. AI in Cancer Care: ProsTIC also highlighted “PETomics” that blends PET imaging with ctDNA using deep learning to predict response to 177Lu-PSMA-617 in mCRPC, alongside open-source AI for PSMA PET/CT segmentation and prognostic biomarker extraction. Cardiovascular Drug Setback: Novartis and Ionis’ pelacarsen (Lp(a) lowering) missed the primary endpoint in the Lp(a)HORIZON phase 3 trial, failing to reduce major cardiovascular events despite lowering Lp(a). Mental Health & Community Care: Canada marks World Suicide Prevention Day (Sept. 10) with a push to change the narrative and strengthen culturally safer, regional prevention supports. Public Health Action: Mississippi expands naloxone vending machines at hospitals to curb overdoses, with fentanyl still a key concern.

Endometriosis Diagnosis: A new report highlights how endometriosis can take a decade to diagnose, and points to emerging tests like PET/MRI that may improve detection—though they’re not widely available in the U.S. Neuroscience & Addiction: A Nature Neuroscience study links social isolation to higher alcohol consumption via a specific brain pathway, with effects that may differ by sex. Mental Health Genetics: A large study finds about half the risk for postpartum psychosis is genetic, underscoring the need for faster recognition and care after childbirth. Cancer Care Imaging: At ProsTIC, researchers discussed PSMA whole-body quantification and updated guidance on Lu-PSMA use, including where it fits before or after surgery. Pharma Regulation & Supply: FDA scrutiny continues for manufacturers, including Cohance’s Form 483 with four observations, while BPOM urged pharma firms to expand clinical trial capacity in Indonesia. Public Health & Policy: California hospitals are challenging new spending-cap penalties under the state’s healthcare affordability rules, arguing they could reduce services. Chronic Disease Prevention: A long-term study links neighborhood walkability with lower type 2 diabetes risk after gestational diabetes, especially noting limits in deprived areas.

FDA Supply Watch: The FDA says it’s working with estradiol transdermal patch makers to boost availability after reports of difficulty getting products, noting supply has nearly doubled over the past year and demand rose after recent menopausal hormone therapy label changes. Breast Cancer Update: The FDA granted accelerated approval to camizestrant (Etcamah) for ESR1-mutated, HR+/HER2– advanced or metastatic breast cancer detected during first-line aromatase inhibitor plus CDK4/6 therapy, based on SERENA-6 results. Urology Care Shift: For muscle-invasive bladder cancer, FDA expanded approval of enfortumab vedotin plus pembrolizumab to cover cisplatin-eligible patients as cystectomy candidates, tightening the treatment pathway. Pediatric Obesity Trend: A new U.S. EHR analysis finds GLP-1 use among children ages 8–11 with obesity is still uncommon but surged since 2019, raising questions about selection and long-term safety. Mental Health Safety: A watchdog group compiled 57 regulatory warnings tied to psychotropic drug risks involving violence or aggression, urging patients and clinicians to review labeling closely. Health Policy: Iowa labor experts discussed unionization challenges amid weaker bargaining laws and corporate pressure, highlighting ongoing worker organizing efforts.

Public Health & Prevention: Curtin University researchers won an Australian Museum Eureka Prize for Societal Impact for the OurFutures Vaping Program, which cut students’ odds of vaping by 65% after one year and has reached 300,000+ young Australians. Pediatrics & Mental Health: A study reported in The Times links coordinated delays in giving kids smartphones until age 14 to an 8% drop in students’ pastoral needs over two years. Vaccines: GSK posted positive Phase II results for an mRNA seasonal flu vaccine candidate and plans a Phase III efficacy trial starting September 2026, aiming to target both HA and NA. Rare Disease & Pharma Ops: Médunik Canada took over exclusive promotion for Diacomit in Canada for Dravet syndrome seizures, and Ionis won FDA approval for Zanvastro (zilganersen) as a disease-modifying therapy for Alexander disease. Biotech Funding: Superluminal Medicines raised $60M to advance a GPCR pipeline, including a Phase 1 plan by end of 2026. Healthcare Supply Chain: DHL partnered with Singapore’s Life Science Incubator and will expand cold-chain healthcare logistics at Changi. Cancer Diagnostics: MedGenome launched OncoTrack MRD, a tumour-informed blood test for detecting residual solid-tumour cancer.

Late-Stage Setback in Rare Disease: Ultragenyx shares plunged nearly 45% after its Phase III apazunersen trial in Angelman syndrome missed primary and secondary endpoints, with the company signaling program review and expense reductions. Drug Pricing Pressure: Pakistan’s pharma industry warned that proposed changes to the drug pricing mechanism could disrupt supplies and affordability, arguing the current 2018 framework was built through broad consultation and upheld by the Supreme Court. FDA Moves on Vaccines: FDA cleared Pfizer-BioNTech’s updated 2026-27 COMIRNATY XFG COVID-19 vaccine for adults 65+ and high-risk people ages 5-64, with shipping set to begin immediately. Oncology + AI in Practice: New reporting highlights how AI is being used in oncology workflows like tumor boards, while clinicians stress transparency and keeping physicians in charge. Clinical Research Watch: Can-Fite BioPharma said blinded overall survival in its LIVERATION trial for namodenoson in advanced HCC looks longer than expected, prompting an earlier interim analysis. Regulatory Scrutiny in Stem Cell Market: FDA issued a warning letter to an Arizona cord-product company over sterility validation and claims that regulators say require approval. Public Health + Recovery: SAMHSA kicked off National Recovery Month with a focus on peer support, recovery-friendly workplaces, and community-based resources.

Commercial Healthcare IT: Cycurion says it won about $800,000 in annual contract spend, including work for a pharmaceutical-industry AI Center of Excellence and new public-health engagements, underscoring growing demand for resilient cybersecurity and AI operating capability. Digital Prevention: Netcompany landed a five-year, £215M+ NHS England contract to build digital infrastructure for England’s adult cancer screening programmes, including plans for digital invitations and home HPV self-testing kits. Oncology Deals: GSK licensed HUTCHMED’s solid-tumour conjugate HMPL-A830 in a deal up to $1.3B, while Treeline and Roche are pairing TLN-121 with Roche’s CD20×CD3 bispecifics in a Phase I B-cell lymphoma study. Biomanufacturing Supply: Nu-Tek is highlighting 100% animal-free peptones and protein hydrolysates at CPHI Global in Milan, aiming to strengthen cell culture media qualification and supply security. Regulatory Watch: A compounding-pharmacy advisory process update outlines what patients and providers should track as FDA review steps move peptides toward potential Category one status. Rare Disease Access: Markel launched a trial travel reimbursement enhancement to help recruit patients for international rare-disease studies. Public Health & Policy: UKHSA reported invasive Aedes aegypti breeding in east London, with risk assessed as very low; and India ordered free H1N1 testing at government facilities amid rising cases. Care Delivery & Value: Research warns Medicare MIPS Value Pathways could disadvantage diagnostic radiologists as radiology-specific measures are reduced.

Autoimmune CAR-T Safety: Novartis and Bristol Myers Squibb paused multiple autoimmune CAR-T trials after safety concerns—Novartis reported fatal immune reactions in Rap-cel studies, while BMS halted Zola-cel enrollment after transient inflammatory events, with cancer trials still moving. Clinical Guidance Update: The American Academy of Neurology and American Headache Society released updated migraine prevention guidance for adults, replacing 2012 recommendations and outlining when to start and how to choose preventive meds. Gene Therapy Push: uniQure filed for FDA accelerated approval of its Huntington gene therapy ifezuntirgene inilparvovec (AMT-130), also submitting to the UK MHRA. Cardiac Imaging Standards: SCCT released updated CCTA recommendations aimed at more consistent reporting of plaque and stenosis, including expanded AI-related workflow guidance. Public Health & Equity: A major international JAMA Network Open review links intimate partner violence to higher child mortality, underscoring violence prevention as a health intervention. Workforce & Policy: Pennsylvania will audit home healthcare agencies after wage theft complaints surged, targeting overtime and pay violations. Health Tech & Research Capacity: Cleveland Clinic opened two major research buildings, adding 300,000 square feet for labs and core services.

EMS Policy Shift: Indiana ends routine ambulance diversions for crowded EDs, allowing diversions only for disasters or critical infrastructure failures. Radiology Payment Scrutiny: A JAMA Network Open study finds CMS devalues radiology services more often than radiology societies’ recommendations, raising concerns about how imaging is priced. Cardiometabolic Food Warning: Research presented at ESC links higher blood xylitol levels to greater major cardiovascular event risk, putting a spotlight on the sugar alcohol found in “sugar-free” gum and toothpaste. Mental Health Genetics: Scientists identify 36 genes tied to OCD and chronic tic disorders, pointing to new treatment targets. Regulatory Innovation in the UK: MHRA launches its first regional NHS “sandbox” in Manchester to speed testing of AI and software medical devices. Hormone Access & Safety: In Wales, women reportedly pose as men to buy testosterone online after prescription barriers, with clinicians warning about dangerously high hormone levels. Biotech & Patents: Purple Biotech gets a USPTO notice of allowance strengthening protection for its CAPTN-3 multispecific antibody platform. Biomanufacturing Capacity: South Korea’s biologics boom continues, but companies still rely on imported biomanufacturing materials. Patient Portal Load: JAMA reports patient portal messaging surged while clinician inboxes became a major workload driver.

Clinical Trial Breakthrough: A randomized trial found a single 10 mg oral hydrocortisone dose improved attention and verbal learning within hours in virally suppressed women with HIV, with daily dosing over four weeks linked to better delayed memory recall. Behavioral Health Funding: HHS/SAMHSA awarded $77M in new grants for substance use prevention, community mental health, suicide prevention, and crisis services. Long COVID Update: In the RECOVER-VITAL trial, extending Paxlovid to up to 25 days showed no clinical benefit for long-COVID cognitive, autonomic, or exercise intolerance symptoms. Drug Pricing Policy: The Trump administration added nine mid-size drugmakers to the Most Favored Nation program, alongside $19.6B in U.S. manufacturing commitments and an expanded active pharmaceutical ingredients reserve. Vaccine Pipeline: GSK advanced its dual-antigen mRNA seasonal flu vaccine into a first-of-its-kind Phase 3 trial after stronger immune responses in Phase 2. Rare Disease Data Access: Two Irish health tech startups are merging to help rare disease patients keep one continuous health and research record instead of losing data across providers and studies. Cancer Care: Enhertu plus Perjeta won EU approval as a new frontline option for unresectable or metastatic HER2-positive breast cancer.

Biotech Leadership & Funding: Immunophotonics closed a $10M Series C and promoted Robert H. Arch, Ph.D., to CEO as it advances IP-001 toward Phase 2 milestones. Medical Devices & Imaging: Profound Medical named Richard Fabian President, signaling continued push in interventional MRI. AI-Enabled Care Access: Rocket Doctor AI reported 43% Q2 revenue growth and a surge in completed U.S. visits after expanding in-network coverage to ~24M lives. Rare Disease & Equity: GeneDx CEO Katherine Stueland earned a 2026 Fierce 50 Health Equity honor, highlighting genomics-driven earlier diagnosis. Epilepsy Pipeline Update: Stoke Therapeutics and Biogen shared 4-year zorevunersen open-label results for Dravet syndrome at EEC, with Phase 3 EMPEROR ongoing. Public Health Guidance: WHO updated typhoid vaccine advice for earlier dosing (9–24 months) amid drug resistance. Policy & Cost Pressure: Trump announced expanded most-favored-nation drug pricing deals projected to save $600B, while KFF flagged a $1,200 breast MRI out-of-pocket bill despite coverage expectations. Care Delivery & Oversight: Radiology experts urged stricter rules around self-interpretation of imaging orders as utilization patterns appear linked to who reads scans. Global Health Capacity: CIDRZ handed over TB lab upgrades and equipment in Zambia to strengthen diagnosis and treatment.

Drug Pricing Push: Trump announced nine more “most-favored-nation” deals with mid-sized pharma, bringing participation to 26 companies and claiming coverage of 89% of branded drugs—aimed at lowering Medicaid prices and boosting U.S. access to newer medicines. Cancer Trial Updates: Final COMBI-I results show spartalizumab plus dabrafenib/trametinib improved overall survival in BRAF V600-mutant melanoma, with higher rates of fever and treatment-related side effects. Breast Cancer Care: New expert discussion highlights how second-line choices in HR+/HER2− metastatic breast cancer hinge on progression timing, disease burden, performance status, and repeat biomarker testing (including ctDNA and tissue reassessment). Cardiovascular Outcomes: VESALIUS-CV analysis reports evolocumab reduced all-cause death by 20% in high-risk patients without prior heart attack or stroke. HIV Treatment: FDA approved Bixlenvo as a once-daily complete switch regimen for virologically suppressed adults with HIV-1. Veterinary Safety: Revival Animal Health recalled certain feline milk replacers after tests found low essential vitamins and minerals for newborn kittens. Medical Tourism: South Korea saw foreign spending on medical services jump 66.5% in July, led by dermatology and plastic surgery. Care Delivery Innovation: A UNC telehealth rapid access prostate cancer program cut referral-to-biopsy time from 161 to 71 days.

Medical Tourism & Spending: South Korea’s foreign visitors spent 213 billion won ($145M) on medical services in July, up 66.5% year over year, with dermatology and plastic surgery still leading but pharmacy spending rising. Cell Therapy Funding: China’s Simnova Biotech raised about $59.5M to speed confirmatory studies for its off-the-shelf CAR-NK therapy and advance in vivo CAR-T work. Drug Access in Hong Kong: Hong Kong approved another new therapy under its “1+” mechanism for chronic spontaneous urticaria, bringing the total to 22. Diagnostics Expansion: Mahajan Imaging and Neuberg Diagnostics are teaming up to build an integrated diagnostics network across seven North Indian states, combining imaging, pathology, genomics and wellness. Cardiometabolic Breakthroughs: Plozasiran (RNAi targeting APOC3) cut triglycerides ~80% at 1 year and reduced acute pancreatitis events in SHASTA-3/4. Care Delivery & Safety: FDA warned patients about quality failures at a California mammography center, including delayed reports and severe image quality issues. Primary Prevention Push: England’s NHS pharmacies will start offering seven-minute cholesterol checks this autumn, with pharmacist-led follow-up for eligible patients. Healthcare Logistics: FedEx earned its 30th IATA CEIV Pharma certification, expanding global capability for temperature-controlled pharmaceutical shipments. AI in Clinical Workflows: A case report highlights risks when AI flags suspicious imaging findings without incorporating clinical context, urging safer integration practices.

AI in Primary Care: Patient.info launched “AskPatient,” a free UK AI symptom checker that pairs conversational help with its clinically reviewed library, aiming to guide users on next steps without diagnosing or prescribing. Cancer Care Standards: ASCO released its first living guideline for recurrent high-grade epithelial ovarian/fallopian tube/primary peritoneal cancer, outlining platinum-based options and biomarker-selected non-platinum sequencing. Pediatric Surgery Innovation: Ontario’s first paediatric scoliosis operation using the Medtronic Mazor robotic spine platform helped a teen achieve near-perfect correction with faster, more precise screw placement. Cardiology Trial Watch: EPIDAURUS was stopped early after potent P2Y12 inhibitors plus a DOAC increased bleeding without reducing ischemic events in AF patients with recent MI. Neurodegeneration Research: New findings link orexin levels to Alzheimer’s cognitive decline, with protective effects tied to stronger sleep spindles and NREM brainwaves. Public Health & Access: HHS is piloting a rapid, five-minute syphilis test for newborn protection, while UHN’s PSA Detect and Protect expands free prostate screening for high-risk Black men. Healthcare Operations: A UPMC/ KLAS report warns AI adoption is outpacing testing and governance, with fewer than half of hospitals running dedicated AI validation before patient-facing use.

Insulin Access Push: California’s CalRx program has distributed 120,000 five-pen packs of insulin glargine at $55 each, aiming to help uninsured patients and pressure big drugmakers as the state’s generic label rolls out slowly. Cardiology Drug Update: Results from the Phase 2b LUMINARA trial show oral relaxin agonist AZD5462 improved cardiac function in chronic heart failure, with findings presented at ESC 2026. Antibiotics in Kids: A randomized trial found azithromycin didn’t reduce wheezing severity in preschoolers in ERs, regardless of whether bacteria were present. Digital Health & Behavior: Experts say digital detoxes fade fast unless people change reward patterns, triggers, and routines—not just put phones away. Maternal Nutrition & Autism: A study of 80,000 mother-child pairs links healthier pregnancy diets with a 22% lower autism diagnosis rate, while stressing it’s an association, not proof of prevention. Medical Tourism Boom: South Korea saw 2.01 million foreign medical tourists in 2025 (+71.9%), and July spending rose 66.5% year over year, led by dermatology and plastic surgery. Healthcare Policy Scrutiny: A report estimates $65B was spent in 2024 on improper ACA and Medicaid enrollments, including duplicated or ineligible coverage.